![](https://library.celltelligence.com/wp-content/uploads/2022/06/Screenshot-2022-06-07-at-07.43.20.png)
$0
CARTITUDE-1 and CARTITUDE-2 Study Updates; Carvykti Demonstrates Durable Responses at 2-Year Follow-Up; Legend Reports Delayed Cases of Parkinsonism; ASCO 2022 Legend Investor Event
On Sunday, June 5, Legend held their ASCO investor event highlighting updated clinical results from Carvykti’s (BCMA CAR-T; cilta-cel) Ph1b/2 CARTITUDE-1 and Ph2 CARTITUDE-2 studies in r/r MM. Below, Celltelligence provides insights on Carvykti’s durable responses in comparison with Abecma (BMS’s BCMA CAR-T), while discussing whether parkinsonism could require a novel mitigation strategy.